Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from 3D Medicines, Inc. ( (HK:1244) ).
3D Medicines has received orphan-drug designation for its PD-L1 inhibitor Envafolimab (KN035) for the treatment of gastric cancer and gastro-esophageal junction cancer, marking the third such designation for the product after biliary tract cancer and soft tissue sarcoma. The new status is supported by Phase II data in advanced gastric/gastro-esophageal junction adenocarcinoma, where Envafolimab combined with FOLFOX achieved a 60% objective response rate and 100% disease control with favorable safety, reinforcing the drug’s clinical profile and strengthening 3D Medicines’ positioning in the global immuno-oncology market as it continues to expand regional licensing and commercialization of this first-in-class subcutaneous PD-L1 inhibitor.
The most recent analyst rating on (HK:1244) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.
More about 3D Medicines, Inc.
3D Medicines Inc. is a biopharmaceutical company focused on oncology, co-developing innovative immuno-oncology drugs such as Envafolimab (KN035), a recombinant PD-L1 inhibitor first approved in China as a subcutaneous injection for advanced MSI-H/dMMR solid tumors. Through partnerships with Alphamab Oncology, Jiangsu Simcere and Glenmark Specialty, the company is building a commercial footprint in mainland China and expanding rights to markets across India, Asia Pacific, the Middle East, Africa, Russia, the CIS and Latin America.
Average Trading Volume: 369,639
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.28B
See more data about 1244 stock on TipRanks’ Stock Analysis page.